Bull
$13.97
Scenario price
$24.110
-0.374 (-1.55%)At close
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Elanco Animal Health Inc is a good buy right now, with a current price of $24.11 and a forward P/E ratio of 22.779. The company has shown strong revenue growth, with Q2 2026 revenue increasing by 10% year-over-year, and a gross margin of 48.17% in the same quarter. The main risk is the negative net income reported in Q4 2025, which was -276 million USD, indicating potential volatility in earnings.
KeyBanc
$30
2026-08-06
KeyBanc
2026-08-06
Price Target
$30
Citi
$34
2026-08-06
Citi
2026-08-06
Price Target
$34
Morgan Stanley
$26
2026-07-22
Morgan Stanley
2026-07-22
Price Target
$26
TD Cowen
$32
2026-06-18
TD Cowen
2026-06-18
Price Target
$32
Morgan Stanley
$23
2026-05-15
Morgan Stanley
2026-05-15
Price Target
$23
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Elanco Expands Antibody Production Capacity with New Facility

Elanco Expands Facility to Enhance Antibody Production Capacity

Elanco Animal Health Director Increases Shareholding

Analysis of ELAN's 52-Week High and Low Points

Elanco (ELAN) Q2 2026 Earnings Call Transcript
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Elanco Animal Health Inc is a good buy right now, with a current price of $24.11 and a forward P/E ratio of 22.779. The company has shown strong revenue growth, with Q2 2026 revenue increasing by 10% year-over-year, and a gross margin of 48.17% in the same quarter. The main risk is the negative net income reported in Q4 2025, which was -276 million USD, indicating potential volatility in earnings.
11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.